TGFB1 and Ehlers-Danlos syndrome, hypermobility type: Agents that influence TGF-β signaling, mast cell stabilization, Wnt/β-catenin pathways, or MMP activity could theoretically attenuate pathological tissue remodeling, yet no clinical trials have systematically evaluated such therapies in hEDS or HSD [45,46].